Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nasus Pharma Ltd. ( (NSRX) ) has issued an update.
On December 29, 2025, Nasus Pharma Ltd. filed a Form 6-K in the United States, publishing its unaudited condensed interim financial statements and management’s discussion and analysis for the six months ended June 30, 2025. The figures show that as of June 30, 2025 the company had total assets of $639,000 against total liabilities of $4.95 million, resulting in a shareholders’ deficit of $4.31 million, while cash and cash equivalents shrank to $203,000. For the first half of 2025 Nasus posted a net loss of $1.25 million, widening from a $871,000 loss a year earlier as operating expenses rose, particularly in research and development and general and administrative costs, and as the fair value of its growing convertible securities liability negatively affected results. The filing highlights Nasus Pharma’s constrained liquidity, heavier reliance on related-party financing and convertible instruments, and a deepening accumulated deficit, factors that are likely to keep the company dependent on additional capital raises and may be closely watched by investors assessing its financial sustainability and development trajectory.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd., based in Tel Aviv, Israel, is a foreign private issuer in the pharmaceutical and life sciences sector, focused on developing its business through continued research and development activities funded primarily via equity and convertible securities rather than operating cash flow. The company remains in a loss-making, development-stage profile, with minimal cash and a significant shareholders’ deficit, underscoring its dependence on external financing and capital markets access.
Average Trading Volume: 6,131
Technical Sentiment Signal: Strong Buy
Find detailed analytics on NSRX stock on TipRanks’ Stock Analysis page.